Kalyani Forge manufactures high-precision forged and machined metal components, such as connecting rods and driveline parts, primarily for automotive, industrial, and marine engine manufacturers.
The company possesses a narrow moat based on technical expertise in complex warm and cold forging and long-standing OEM relationships; however, this is contradicted by chronically low returns on capital (avg ROCE 6%) and thin net margins (avg 1%).
Management is currently pivoting from low-margin legacy business toward high-value machined parts and has recently commissioned a 4,000T press to expand its product range, but historical reinvestment has failed to generate returns significantly above the cost of capital.
The investment collapsed because the company's pivot to high-value machined parts failed to outpace its rising cost structure and structural inefficiencies. The material weaknesses in financial controls and inventory valuation issues identified in FY25 proved to be systemic rather than transitional, leading to significant asset write-downs. As interest coverage remained thin and capital was tied up in unconfirmed receivables, the company lacked the liquidity to service its debt or maintain the new 4,000T press, resulting in a slow liquidation of shareholder value through persistent sub-cost-of-capital returns.
RichFakir rates Kalyani Forge Ltd's business quality as poor — 25/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Kalyani Forge Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Kalyani Forge Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Kalyani Forge Ltd's fair value is about ₹77 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →